Investors

OvaScience is a life sciences company focused on the discovery, development and commercialization of new treatments for infertility.

OVAS (Common Stock)
Price & Exchange
$27.53
NASDAQ
Change (%)
 Stock is Up 0.01 (0.04%)
Volume
422,326
07/06/15      4:00 p.m. ET

Minimum 20 minute delay
Refresh quote

Investor Overview

Recent News

More »
DateTitle 
06/18/15OvaScience to Present at the JMP Securities Life Sciences Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 18, 2015-- OvaScience℠ (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that Company management will present at the JMP Securities Life Sciences Conference on Tuesday, June 23, 2015 at 9:00 am ET at the St. Regis New York. A live audio webcast of the presentation can be accessed by visiting the Investors s... 
Printer Friendly Version
06/17/15OvaScience’s AUGMENT Treatment Shows Improved Pregnancy Rates and Live Births in Women with Poor Prognoses as Reported by Physicians During Annual International Fertility Meeting
- Additional Baby Born with AUGMENT Treatment - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 17, 2015-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced that physicians continue to report improvements in pregnancy rates and live births with the AUGMENTSM treatment in women with very poor prognoses, including those with poor egg health and embryo q... 
Printer Friendly Version
06/05/15OvaScience Expands Senior Team with Two New Key Hires
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 5, 2015-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today two new positions that support OvaScience’s expanding international operations. John Eisel has joined the Company as Executive Vice President of Global Site Operations, and Gabriel M. Cohn, M.D., has joined as Head of Medical Affairs and Trans... 
Printer Friendly Version
06/05/15OvaScience Welcomes John Howe, M.D., Former President and CEO of Project HOPE, to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 5, 2015-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today the appointment of John P. Howe, III, M.D., former President and Chief Executive Officer of Project HOPE, to the OvaScience Board of Directors. “Dr. Howe’s many accomplishments, including overseeing Project HOPE through its expansion o... 
Printer Friendly Version

Upcoming Events

More »
There are currently no events scheduled.
Powered by Thomson Reuters
Data Provided by Thomson Reuters
Minimum 20 minutes delayed